ROLE OF MATRIX METALLOPROTEINASE-9 IN THE BASEMENT MEMBRANE DESTRUCTION OF SUPERFICIAL UROTHELIAL CARCINOMAS
- 1 April 1999
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 161 (4) , 1359-1363
- https://doi.org/10.1016/s0022-5347(01)61684-7
Abstract
This study was conducted to clarify which matrix metalloproteinases (MMPs) play a key role in destruction of the underlying basement membrane (BM) of superficial urothelial carcinomas. Urine concentrations of MMP-9 and tissue inhibitors of matrix metalloproteinase-1 (TIMP-1) were also measured. Overexpression of MMP-1, MMP-2 and MMP-9 was analyzed immunohistochemically in 60 patients with transitional cell carcinomas of the urothelium (41 were pTa or pis, 19 were pT1-4), and compared them with type IV collagen expression in tumor BM. In 33 of them, urine concentrations of MMP-9 and TIMP-1 were measured by one-step sandwich enzyme immunoassay. Positive expression of MMP-1, MMP-2 and MMP-9 was found in 53%, 17%, and 65% of tumors, respectively. Only MMP-9 expression rates were increased with grades and stages (p = 0.03). In pTa and pis tumors, type IV collagen expression was reduced in 17 of 26 (65.4%), and it was associated with positive MMP-9 expression (p = 0.0283). MMP-9 was detected in all urine samples of urothelial cancer patients, while urine TIMP-1 was detectable in 18 of 33 patients. In 16 healthy volunteers, both of them were below detectable levels. Balance between urinary MMP-9 and TIMP-1 were particularly kept in superficial urothelial carcinomas with intact tumor BM. Tumor BM status, however, was not associated with urinary MMP-9 or TIMP-1 levels. These results suggest that MMP-9 plays a key role in the invasion step of superficial urothelial carcinomas. Detection of urinary MMP-9 may become a new, non-invasive mean for the diagnosis of urothelial carcinomas.Keywords
This publication has 12 references indexed in Scilit:
- Strong Correlation of Basement Membrane Degradation With P53 Inactivation and/or MDM2 Overexpression in Superficial Urothelial CarcinomasJournal of Urology, 1997
- Matrix metalloproteinase inhibitorsInvestigational New Drugs, 1997
- Matrix metalloproteinasesBritish Journal of Surgery, 1997
- Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinomaCancer, 1996
- Overexpression of Matrix Metalloproteinase 9 Gene in Hepatocellular Carcinoma With Invasive PotentialHepatology, 1996
- Regulation of matrix metalloproteinases following cellular transformationJournal of Cellular Physiology, 1996
- A one-step sandwich enzyme immunoassay for inactive precursor and complexed forms of human matrix metalloproteinase 9 (92 kDa gelatinase/type IV collagenase, gelatinase B) using monoclonal antibodiesClinica Chimica Acta; International Journal of Clinical Chemistry, 1994
- SERUM LEVELS OF A TISSUE INHIBITOR OF METALLOPROTEINASES‐1 (TIMP‐1) IN BLADDER CANCER PATIENTSInternational Journal of Urology, 1994
- Prognostic significance of type IV collagen and laminin immunoreactivity in urothelial carcinomas of the bladderCancer, 1990
- Rapid one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases An application for rheumatoid arthritis serum and plasmaJournal of Immunological Methods, 1990